GlobeNewswire: Autolus Limited Contains the last 10 of 116 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T01:31:45ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2022/05/12/2442194/0/en/Autolus-Therapeutics-to-Present-Four-Clinical-Data-Updates-at-the-European-Hematology-Association-Congress.html?f=22&fvtc=4&fvtv=53568Autolus Therapeutics to Present Four Clinical Data Updates at the European Hematology Association Congress2022-05-12T14:51:51Z<![CDATA[- AUTO4: oral presentation on initial clinical experience in peripheral T cell lymphoma- AUTO1/22: oral presentation on initial experience in r/r pediatric B-cell acute lymphoblastic leukemia- obe-cel: poster presentation in r/r primary CNS lymphoma- obe-cel: poster presentation in r/r B-non-Hodgkins lymphoma and chronic lymphoblastic leukemia- Conference call to be held on June 13, 2022 at 7:30 am EST/12:30 pm BST]]>https://www.globenewswire.com/news-release/2022/05/05/2436607/0/en/Autolus-Therapeutics-Reports-First-Quarter-2022-Financial-Results-and-Operational-Progress.html?f=22&fvtc=4&fvtv=53568Autolus Therapeutics Reports First Quarter 2022 Financial Results and Operational Progress2022-05-05T11:00:00Z<![CDATA[- Conference call to be held on May 5, 2022 at 8:30 am ET/1:30 pm BST - - Conference call to be held on May 5, 2022 at 8:30 am ET/1:30 pm BST -]]>https://www.globenewswire.com/news-release/2022/05/02/2434002/0/en/Autolus-Therapeutics-to-Present-Three-Novel-Cell-Programming-Approaches-at-the-American-Society-of-Gene-Cell-Therapy-ASGCT-25th-Annual-Meeting-May-16-19-2022.html?f=22&fvtc=4&fvtv=53568Autolus Therapeutics to Present Three Novel Cell Programming Approaches at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting, May 16-19, 2022 2022-05-02T20:31:00Z<![CDATA[Developing cell programming capabilities to improve our pipeline of precise, controlled and highly active products Developing cell programming capabilities to improve our pipeline of precise, controlled and highly active products]]>https://www.globenewswire.com/news-release/2022/04/25/2427994/0/en/FDA-Grants-Regenerative-Medicine-Advanced-Therapy-RMAT-designation-to-Autolus-CAR-T-cell-therapy-obe-cel-for-the-treatment-of-adult-B-ALL.html?f=22&fvtc=4&fvtv=53568FDA Grants Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus’ CAR T cell therapy, obe-cel, for the treatment of adult B-ALL2022-04-25T11:01:00Z<![CDATA[LONDON, April 25, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead gene therapy obecabatagene autoleucel (obe-cel), a CD19-directed autologous chimeric antigen receptor (CAR) T therapy that is being investigated in the ongoing FELIX Phase 2 study of adult relapsed / refractory B-Acute Lymphocytic Leukemia (ALL).]]>https://www.globenewswire.com/news-release/2022/04/25/2427987/0/en/Autolus-Therapeutics-to-Report-First-Quarter-2022-Financial-Results-and-Host-Conference-Call-on-May-5.html?f=22&fvtc=4&fvtv=53568Autolus Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 52022-04-25T11:00:00Z<![CDATA[LONDON, April 25, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its first quarter 2022 financial results and operational highlights before open of U.S. markets on Thursday, May 5, 2022.]]>https://www.globenewswire.com/news-release/2022/03/31/2413711/0/en/Autolus-Therapeutics-Receives-EMA-Orphan-Medical-Product-Designation-for-obe-cel-for-Treatment-of-Acute-Lymphoblastic-Leukemia.html?f=22&fvtc=4&fvtv=53568Autolus Therapeutics Receives EMA Orphan Medical Product Designation for obe-cel for Treatment of Acute Lymphoblastic Leukemia2022-03-31T11:00:00Z<![CDATA[LONDON, March 31, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that the European Medicines Agency (EMA) has granted obe-cel, Autolus’ leading CAR T clinical candidate, Orphan Medical Product Designation for treatment of acute lymphoblastic leukemia (ALL) patients.]]>https://www.globenewswire.com/news-release/2022/03/29/2411738/0/en/Autolus-Therapeutics-to-Participate-in-Conferences-During-April-2022.html?f=22&fvtc=4&fvtv=53568Autolus Therapeutics to Participate in Conferences During April 20222022-03-29T11:00:00Z<![CDATA[- Wells Fargo Annual Biotech Forum on April 12 and 13 -]]>https://www.globenewswire.com/news-release/2022/03/10/2400726/0/en/Autolus-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results-and-Operational-Progress.html?f=22&fvtc=4&fvtv=53568Autolus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Progress2022-03-10T12:00:00Z<![CDATA[- Conference call to be held on March 10, 2022 at 8:30 am ET/1:30 pm GMT - - Conference call to be held on March 10, 2022 at 8:30 am ET/1:30 pm GMT -]]>https://www.globenewswire.com/news-release/2022/03/03/2396089/0/en/Autolus-Therapeutics-Announces-Publication-Describing-Novel-Cell-Programming-Technology.html?f=22&fvtc=4&fvtv=53568Autolus Therapeutics Announces Publication Describing Novel Cell Programming Technology2022-03-03T12:00:00Z<![CDATA[- Publication describing a novel technology that provides for very low levels of expression of one programming module relative to another programming module1]]>https://www.globenewswire.com/news-release/2022/02/21/2388540/0/en/Autolus-Therapeutics-to-Report-Fourth-Quarter-and-Full-Year-2021-Financial-Results-and-Host-Conference-Call-on-March-10.html?f=22&fvtc=4&fvtv=53568Autolus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on March 102022-02-21T12:00:00Z<![CDATA[LONDON, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its fourth quarter and full year 2021 financial results and operational highlights before open of U.S. markets on Thursday, March 10, 2022.]]>